Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aminophenazone + caffeine + chlorphenamine is a fixed-dose combination medication developed and marketed by Anke Bio for the symptomatic relief of the common cold and influenza. The formulation consists of three active ingredients: aminophenazone, an analgesic and antipyretic that reduces fever and pain by inhibiting cyclooxygenase (COX) enzymes; chlorphenamine maleate, a first-generation antihistamine that acts as a histamine H1 receptor antagonist to relieve symptoms such as sneezing, rhinorrhea, and watery eyes; and caffeine, a central nervous system stimulant that acts as an adenosine receptor antagonist. Caffeine is included to enhance the analgesic efficacy of aminophenazone and to mitigate the sedative effects commonly associated with chlorphenamine. This combination is approved in China and is typically administered orally in capsule form for the treatment of fever, headache, sore throat, and nasal congestion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aminophenazone + caffeine + chlorphenamine.